Telik, Inc. (TELK) announced that the U.S. Food and Drug Administration or FDA has removed the partial hold on TELCYTA (canfosfamide HCl, TLK286) clinical trials. The company said that this action follows a complete review of TELCYTA data by the agency and permits the resumption of TELCYTA clinical development.
The company noted that its most advanced drug development candidates are TELCYTA, a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non- small cell lung cancer; and TELINTRA, which is in clinical development for the treatment of myelodysplastic syndrome.
For comments and feedback: editorial@rttnews.com